Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: 2020-05-22
Affiliations: 7
Go to article